Insulin resistance and metabolic profile in antipsychotic naïve schizophrenia patients

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 34, Issue 7, 2010, Pages 1202-1207

  Dasgupta, Anindya ^a   Singh, Om Prakash ^a   Rout, Jayanta Kumar ^a   Saha, Tanmay ^a   Mandal, Sonai ^a  

^a BURDWAN MEDICAL COLLEGE AND HOSPITAL   (India)

Author keywords

Dyslipidemia; Homoeostatic model assessment (HOMA); Insulin resistance; Schizophrenia

Indexed keywords

CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; DRUG EXPOSURE; FEMALE; GLUCOSE BLOOD LEVEL; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MALE; SCHIZOPHRENIA;

ADULT; BLOOD GLUCOSE; BODY MASS INDEX; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN RESISTANCE; LINEAR MODELS; LIPID METABOLISM; MALE; MIDDLE AGED; SCHIZOPHRENIA; YOUNG ADULT;

EID: 77956426326     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2010.06.011     Document Type: Article

References (47)

1. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 2004, 65:267-272. American Diabetes Association, American Psychiatric AssociationAmerican Psychiatric Association, American Association of Clinical EndocrinologistsAmerican Association of Clinical Endocrinologists, North American Association for the Study of ObesityNorth American Association for the Study of Obesity.
2. American Psychiatric Association Diagnostic and statistical manual of mental disorders 1994, American Psychiatric Association, Washington, DC. 4th edition.
3. Arranz B., Rosel P., Ramirez N., Duenas R., Fernandez P., Sanchez J.M., et al. Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naïve first-episode schizophrenia patients. J Clin Pstychiatry 2004, 65:1335-1342.
4. Burstein M., Scholnic H.R., Morfin R.J. Rapid method for isolation of lipoproteins from human serum by precipitation with polyanions. Lipid Res 1970, 11:583-595.
5. Cohn T.A., Reminton G., Zipursky R.B., Azad A., Connolly P., Wolever T.M. Insulin resistance and adiponectin levels in drug-free patients with schizophrenia: a preliminary report. Can J Psychiatry 2006, 51:382-386.
6. Fan X., Goff D.C., Henderson D.C. Inflammation and schizophrenia. Expert Rev Neurother 2007, 7(7):789-796.
7. Fernandez-Egea E., Miller B., Bernardo M., Doner T., Kirkpatrick B. Parental history of type 2 diabetes in patients with nonaffective psychosis. Schizophr Res 2008, 98:302-306.
8. Fernandez-Egea E., Bernardo M., Parellada E., Justica A., Garcia-Rizo C., Esmatjes E., et al. Glucose abnormalities in the siblings of people with schizophrenia. Schizophr Res 2008, 103:110-113.
9. Fernandez-Egea E., Bernardo M., Donner T., Conget I., Parellada E., Justicia A., et al. Metabolic profile of antipsychotic-naïve individuals with non-affective psychosis. Br J Psychiatry 2009, 194:434-438.
10. Friedewald W.T., Levy R.I., Fredickson D.S. Estimation of concentration of LDL cholesterol in plasma, without use of preparative ultracentrifuge. Clin Chem 1972, 18:499-502.
11. Haffner S.M., Miettinen H., Stern M.P. The homeostasis model in the San Antonio Heart Study. Diabetes Care 1997, 20:1087-1092.
12. Haffner S.M. The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. Am J Cardiol 2006, 97:3A-11A.
13. Hales C.N., Barker D.J. The thrifty phenotype hypothesis. Br Med Bull 2001, 60:5-20.
14. Keskin M., Kurtoglu S., Kendirci M., Atabek E.M., Yazici C. Homeostasis model assessment is more reliable than the fasting glucose/insulin ratio and quantitative insulin sensitivity check index for assessing insulin resistance among obese children and adolescents. Pediatrics 2005, 115(4):e500-e503.
15. Koenig J.I., Kirkpatrick B., Lee P. Glucocorticoid hormones and early brain development in schizophrenia. Neuropsychopharmacology 2002, 27:309-318.
16. Kohen D. Diabetes mellitus and schizophrenia: historical perspective. Br J Psychiatry 2004, 184(suppl 47):s64-s66.
17. Kreier F, Kap YS, Mettenleier TC, van Heijningen C, van der Vliet J, Kalsbeek A, et al. Tracing from fat tissue, liver and pancreas: a neuroanatomical framework for the role of the brain in type 2 diabetes. Endocrinology 2006, 147:1140-1147.
18. Kristiansen O.P., Mandrup-Poulsen T. Interleukin-6 and diabetes: the good, the bad, or the indifferent?. Diabetes 2005, 54(suppl 2):s114-s124.
19. Kumar H.K., Yadav R.K., Prajapati J., Reddy C.V., Raghunath M., Modi K.D. Association between thyroid hormones, insulin resistance, and metabolic syndrome. Saudi Medical Journal 2009, 30(7):907-911.
20. Kunugi H., Nanko S., Murray R.M. Obstetric complications and schizophrenia prenatal underdevelopment and subsequent neurodevelopmental impairment. Br J Psychiatry 2001, 178(suppl 40):s25-s29.
21. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
22. McEvoy J.P., Meyer J.M., Goff D.C., Nasrallah H.A., Davis S.M., Sullivan L., et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005, 80:19-32.
23. Mukherjee S., Schnur D.B., Reddy R. Family history of type 2 diabetes in schizophrenic patients. Lancet 1989, 1(8636):495.
24. Matsumoto K., Miyake S., Yano M., Ueki Y., Yamaguchi Y., Akazawa S., Tominaga Y. Glucose tolerance, insulin secretion, and insulin sensitivity in nonobese and obese Japanese subjects. Diabetes Care 1997, 20:1562-1568.
25. Osmond C., Barker D.J. Fetal, infant, and childhood growth are predictors of coronary heart disease, diabetes, and hypertension in adult men and women. Environ Health Perspect 2000, 108:s545-s553.
26. Ozanne S.E., Fernandez-Twinn D., Hales C.N. Fetal growth and adult diseases. Semin Perinatol 2004, 28:81-87.
27. Ravelli A.C., van der Meulen J.H., Michels R.P., Osmond C., Barker D.J., Hales C.N., et al. Glucose tolerance in adults after prenatal exposure to famine. Lancet 1998, 351(9097):173-177.
28. Rifai N., Warnick G.R. Lipids, lipoproteins, apolipoproteins, and other cardiovascular risk factors. Tietz textbook of clinical chemistry and molecular diagnostics 2006, 944. Saunders, Elsevier, New Delhi. 4th edition. C.A. Burtis, E.R. Ashwood, D.E. Bruns (Eds.).
29. Roeschlau P., Bernt E., Gruber W.A. Estimation of serum cholesterol. Clin Biochem 1974, 12:226.
30. Ryan M.C., Collins P., Thakore J.H. Impaired fasting glucose tolerance in first episode, drug-naïve patients with schizophrenia. Am J Psychiatry 2003, 160:284-289.
31. Sacks D.B. Carbohydrates. Tietz textbook of clinical chemistry and molecular diagnostics 2006, 870-871. Saunders, Elsevier, New Delhi. 4th edition. C.A. Burtis, E.R. Ashwood, D.E. Bruns (Eds.).
32. Saha S., Chant D., McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?. Arch Gen Psychiatry 2007, 64:1123-1131.
33. Scigliano G., Ronchetti G., Girotti F. Autonomic nervous system and risk factors for vascular disease. Effects of autonomic unbalance in scizophrenia and Parkinson's disease. Neurol Sci 2008, 29(1):15-21.
34. Sengupta S., Parrilla-Escobar M.A., Klink R., Fathalli F., Ying Kin N.G., Stip E., et al. Are metabolic indices different between drug-naïve first-episode psychosis patients and healthy controls?. Schizophr Res 2008, 102(1-3):329-336.
35. Smith R.C., Lindenmayer J.P., Davis J.M., Kelly E., Viviano T.F., Cornwell J., Hu Q., Khan A., Vaidhyanathaswamy S. Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized 5-month study. J Clin Psychiatry 2009, 70(11):1501-1513.
36. Spelman L.M., Walsh P.I., Sharifi N., Collins P., Thakore J.H. Impaired glucose tolerance in first-episode drug-naïve patients with schizophrenia. Diabet Med 2007, 24:481-485.
37. Strassnig M., Brar J.S., Ganguli R. Increased caffeine and nicotine consumption in community-dwelling patients with schizophrenia. Schizophr Res 2006, 86:269-275.
38. Stumvoll M., Mitrakou A., Pimenta W., Jenssen T., Yki-Jarvinen H., Van Haeften T., Renn W., Gerich J. Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care 2000, 23:295-301.
39. Tai E.S., Lim S.C., Tan B.Y., Chew S.K., Heng D., Tan C.E. Screening for diabetes mellitus-a two-step approach in individuals with impaired fasting glucose improves direction of those at risk of complications. Diabet Med 2000, 17:771-775.
40. Tai E.S., Tan M.L., Stevens R.D., Low Y.L., Muehlbauer M.J., Goh D.L., et al. Insulin resistance is associated with a metabolic profile of altered protein metabolism in Chinese and Asian-Indian men. Diabetologia 2010 Apr, 53(4):756-767.
41. Tilg H., Moschen A.R. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006, 6:772-783.
42. van Nimwegen L.J., Storosum J.G., Blumer R.M., Allick G., Venema H.W., de Haan L., Becker H., van Amelsvoort T., Ackermans M.T., Fliers E., Serlie M.J., Sauerwein H.P. Hepatic insulin resistance in antipsychotic naive schizophrenic patients: stable isotope studies of glucose metabolism. J Clin Endocrinol Metab. 2008, 93(2):572-577.
43. Verma S.K., Subramaniam M., Liew A., Poon L.Y. Metabolic risk factors in drug-naive patients with first-episode psychosis. J Clin Psychiatry 2009, 70(7):997-1000.
44. Victoriano M., Hermier D., Even P.C., Fromentin G., Huneau J.F., Tomé D., de Beaurepaire R. Early perturbation in feeding behaviour and energy homeostasy in olanzapine-treated rats. Psychopharmacology 2009, 206(1):167-176.
45. Wahlbeck K., Forsen T., Osmond C., Barker D.J., Eriksson J.G. Association of schizophrenia with low maternal body mass index, small size at birth, and thinness during childhood. Arch Gen Psychiatry 2001, 58:48-52.
46. Wallace T.M., Levy J.C., Matthews D.R. Use and abuse of HOMA modelling. Diabetes Care 2004, 27:1487-1495.
47. Yasui-Furukori N., Sato Y., Furukori H., Saito M., Nakagami T., Kaneko S. Glucose metabolism in Japanese schizophrenia patients treated with risperidone or olanzapine. J Clin Psychiatry 2009, 70(1):95-100.